Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Abstract Introduction The efficacy and safety of lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, were investigated in patients with moderate-to-severe atopic dermatitis (AD) up to 52 weeks in phase 3 trials. This analysis evaluates safety and maintenance of response throu...

Full description

Saved in:
Bibliographic Details
Main Authors: Emma Guttman-Yassky, Stephan Weidinger, Eric L. Simpson, Melinda Gooderham, Alan D. Irvine, Lynda Spelman, Jonathan I. Silverberg, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaçi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-06-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Efficacy
Lebrikizumab
Long-term
Online Access:https://doi.org/10.1007/s13555-025-01452-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01452-9

Similar Items